rs1183201 — SLC17A1

Intronic variant in SLC17A1 (NPT1), the renal apical urate efflux transporter; the T allele impairs renal urate secretion, raising serum uric acid and increasing gout risk, with protective A allele frequency ~46% in Europeans

See your personal result for SLC17A1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC17A1 rs1183201 — The Renal Urate Gate

The kidneys manage roughly two-thirds of daily uric acid excretion, and they accomplish this through a precise interplay of transporters on the proximal tubule epithelium. On the apical (urine-facing) membrane, proteins export uric acid from tubular cells into the tubular lumen for elimination; on the basolateral side, others reclaim it from urine back into the bloodstream. NPT111 NPT1
sodium-dependent phosphate transport protein 1, encoded by SLC17A1, sits on the apical membrane and functions as a urate efflux transporter — it pumps uric acid out of tubular cells into urine. rs1183201 is an intronic variant in SLC17A1 that tags a haplotype block spanning the SLC17A1–SLC17A3–SLC17A4 gene cluster on chromosome 6; it is in high linkage disequilibrium (r² = 0.97) with rs1165205 in the nearby SLC17A3 gene, so it captures genetic variation across this entire renal secretory locus.

The Mechanism

NPT1 is primarily known as a phosphate-sodium cotransporter in the brush border membrane of kidney proximal tubule cells, but functional studies demonstrate that it also mediates significant urate transport. Acting as part of a broader "urate transportsome"22 "urate transportsome"
a multiprotein complex coordinating bidirectional urate movement at the proximal tubule apical membrane, NPT1 opposes the major reabsorptive transporter URAT1 (SLC22A12). Variants that reduce NPT1 efflux activity shift the reabsorption–secretion balance toward retention, raising the serum urate setpoint.

The functional link between rs1183201 and transporter activity is illuminated by a neighbouring missense variant, rs1165196 (T269I, in LD with rs1183201), which encodes a gain-of-function NPT1 that exports more urate than the wild-type protein33 more urate than the wild-type protein
Sakiyama et al. 2016: NPT1 I269T variant increased urate transport without altering membrane expression, consistent with enhanced transport kinetics. This confirms that altered NPT1 activity is the biological signal at this locus, even though rs1183201 itself is intronic and likely acts by modifying expression or splicing of SLC17A1 (and possibly SLC17A3) rather than changing protein sequence directly.

The Evidence

The association of rs1183201 with serum uric acid is robustly established. A meta-analysis of 28,141 Europeans across 14 genome-wide association studies identified rs1183201 as genome-wide significant for serum urate (p = 3.0×10⁻¹⁴)44 genome-wide significant for serum urate (p = 3.0×10⁻¹⁴)
Kolz et al. 2009, PLoS Genetics; nine independent urate loci identified, including SLC2A9, ABCG2, and SLC17A1. Each copy of the protective A allele lowers serum uric acid by 0.062 standard deviation units (approximately 0.05–0.08 mg/dL), with homozygous AA individuals having the lowest serum urate and TT homozygotes the highest.

Independent replication confirmed the gout association. In 971 New Zealand gout cases and 1,742 controls from Caucasian and Polynesian cohorts, the protective allele showed OR 0.67 in Caucasians (p = 3.0×10⁻⁶) and OR 0.74 in Polynesians (p = 3.0×10⁻³)55 the protective allele showed OR 0.67 in Caucasians (p = 3.0×10⁻⁶) and OR 0.74 in Polynesians (p = 3.0×10⁻³)
Hollis-Moffatt et al. 2012, Arthritis Research & Therapy — genome-wide significance for gout risk when both cohorts were combined. In Chinese Han males (622 gout cases, 917 controls), the protective allele showed OR 0.572 (p = 1.39×10⁻⁷) for gout and was also significantly associated with serum uric acid concentrations66 OR 0.572 (p = 1.39×10⁻⁷) for gout and was also significantly associated with serum uric acid concentrations
Zhou et al. 2015, BMC Medical Genetics. The consistency across European, Polynesian, and East Asian populations gives this locus strong evidence confidence.

Practical Actions

Elevated serum urate resulting from reduced renal secretion capacity is particularly responsive to dietary purine management. Unlike SLC2A9 or ABCG2 variants (which affect reabsorption), NPT1 reduction is on the secretion side: the kidney is less able to push urate out. Reducing the input — dietary purine load — directly offsets this secretory deficit. High-purine foods (red meat, organ meats, shellfish) raise uric acid production fastest; fructose-sweetened beverages increase uric acid synthesis independently of purine content and should be specifically targeted.

Serum uric acid monitoring is the most direct way to establish your personal setpoint and detect early hyperuricemia before the first gout flare. TT homozygotes should aim for a serum urate target below 6.0 mg/dL (360 µmol/L), the threshold below which monosodium urate crystals dissolve. AT heterozygotes have an intermediate risk and benefit from periodic monitoring, especially during weight gain or increased alcohol intake, which both raise serum urate.

Vitamin C supplementation has specific evidence in the uric acid context: at 500–1,000 mg daily it lowers serum urate by approximately 0.5 mg/dL through competitive inhibition of renal urate reabsorption — an effect that partially compensates for reduced secretory capacity at this locus.

Interactions

rs1183201 operates at the secretory arm of renal urate handling. The most clinically relevant interaction is with rs2231142 in ABCG2 — the breast cancer resistance protein that drives the second major apical secretion pathway for urate. ABCG2 variants dramatically reduce secretion (Q141K in rs2231142 reduces ABCG2 activity by ~50%), and combined SLC17A1 + ABCG2 impairment compresses both secretory routes simultaneously, producing substantially higher serum urate than either variant alone. This compound effect is most relevant in East Asian populations, where both variants are common.

There is also documented LD with rs1165205 (SLC17A3) and potential regulatory co-variation within the SLC17A1/SLC17A3/SLC17A4 gene cluster. The functional significance of SLC17A3 and SLC17A4 in urate handling is less well-characterized than SLC17A1, but the linked haplotype likely encompasses regulatory variation across all three genes.

Nutrient Interactions

purine increased_need

Genotype Interpretations

What each possible genotype means for this variant.

AA High NPT1 Secretory Capacity Beneficial

Protective genotype — efficient renal urate secretion, lower gout risk

You carry two copies of the protective A allele at rs1183201. Population studies show this genotype is associated with the lowest serum uric acid levels in the SLC17A1 locus, approximately 0.12 SD (roughly 0.1 mg/dL) lower urate compared to TT carriers. This genotype is found in approximately 12% of people globally and about 21% of Europeans. Your kidney's NPT1 urate secretion pathway appears to function at the higher end of the population range, supporting efficient urate clearance. Your baseline gout risk from this locus is reduced relative to the population average.

AT Intermediate NPT1 Function Intermediate

One risk allele — modestly elevated serum urate, mild increased gout risk

At the molecular level, one NPT1 haplotype at this locus tags a normal-to-high secretory capacity and one tags a reduced secretory capacity, resulting in intermediate net urate excretion through this pathway. The per-allele effect size (~0.062 SD per A allele in the meta-analysis) means heterozygotes sit at an intermediate serum urate setpoint. In absolute terms this is approximately 0.05–0.08 mg/dL lower than TT homozygotes — small enough to rarely be clinically meaningful on its own, but worth managing alongside other modifiable risk factors. The AT genotype represents intermediate secretory capacity.

TT Reduced NPT1 Secretory Capacity High Risk

Two risk alleles — elevated serum urate baseline, increased gout risk

With both NPT1 alleles on the reduced-efficiency haplotype, renal secretion of uric acid through this pathway is persistently lower than in protective-allele carriers. The SLC17A1 locus explains approximately 0.19% of the variance in serum uric acid in European populations — modest as a standalone effect, but compounding significantly with variants in ABCG2 (rs2231142, the other major renal urate secretor) and SLC2A9 (the major urate reabsorber). In Polynesian populations, where gout prevalence is among the highest globally, the TT genotype was associated with OR ~0.74 relative to A-allele carriers, and in Han Chinese males the protective allele showed OR 0.572 — confirming that this locus is clinically meaningful across multiple ancestries and not just a statistical artifact of European GWAS. Hyperuricemia from impaired renal secretion is particularly responsive to vitamin C supplementation (500–1,000 mg/day) and to reducing dietary fructose, both of which act on pathways that compensate specifically for secretory deficits.